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Abstract
Background: Drug resistance is a major problem in leishmaniasis chemotherapy. RNA expression profiling using DNA
microarrays is a suitable approach to study simultaneous events leading to a drug-resistance phenotype. Genomic analysis
has been performed primarily with Old World Leishmania species and here we investigate molecular alterations in antimony
resistance in the New World species L. amazonensis.
Methods/Principal Findings: We selected populations of L. amazonensis promastigotes for resistance to antimony by step-
wise drug pressure. Gene expression of highly resistant mutants was studied using DNA microarrays. RNA expression
profiling of antimony-resistant L. amazonensis revealed the overexpression of genes involved in drug resistance including
the ABC transporter MRPA and several genes related to thiol metabolism. The MRPA overexpression was validated by
quantitative real-time RT-PCR and further analysis revealed that this increased expression was correlated to gene
amplification as part of extrachromosomal linear amplicons in some mutants and as part of supernumerary chromosomes in
other mutants. The expression of several other genes encoding hypothetical proteins but also nucleobase and glucose
transporter encoding genes were found to be modulated.
Conclusions/Significance: Mechanisms classically found in Old World antimony resistant Leishmania were also highlighted
in New World antimony-resistant L. amazonensis. These studies were useful to the identification of resistance molecular
markers.
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Introduction
Leishmaniasis refers to a spectrum of parasitic diseases caused by
protozoan parasites belonging to the genus Leishmania.T h ed i s e a s e s
are classified as neglected tropical diseases according to the World
Health Organization (WHO) and constitute a public health problem
in many developing countries of East Africa, the Indian subcontinent
and Latin America. Human leishmaniasis has a prevalence of 12
million cases, with an estimated population of 350 million at risk and
an incidence of 2 million new cases annually. Depending on
Leishmania species, the host immune response, and environmental
factors, leishmaniasis exhibits a broad spectrum of clinical manisfes-
tations [1]. For example, in the New World, Leishmania (Leishmania)
amazonensis, Leishmania (Viannia) guyanensis and Leishmania (Viannia)
braziliensis are the causative agents of cutaneous and mucocutaneous
leishmaniasis while Leishmania (L.) infantum chagasi is the aetiological
agent of American visceral leishmaniasis [1,2].
Pentavalent antimonials (Sb
V), such as sodium stibogluconate
(PentostamH) and meglumine antimoniate (GlucantimeH) have
been the first-line drugs in the treatment of all forms of
leishmaniasis in South America, North Africa, Turkey, Bangladesh
and Nepal. One major drawback of the Sb
V treatment is the
emergence of resistance. For example, more than 60% of patients
with visceral leishmaniasis in Bihar State in India are unresponsive
to treatment with Sb
V antimonials [3]. The emergence of
antimony resistance is related to inappropriate drug exposure
resulting in a build-up of subtherapeutic blood levels and
increasing tolerance of parasites to Sb
V [4]. Other drugs have
been introduced as alternative chemotherapeutic agents including
pentamidine, paromomycin, liposomal amphotericin B and
miltefosine. However, either side effects, lower effectiveness or
high cost have limited their use [5].
The mechanisms involved in antimony resistance in Leishmania
are partially understood. Antimonial drugs are administered as
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V, a prodrug that is reduced to Sb
III, the trivalent and
biologically active Sb form [6,7]. However, the site of this
reduction (macrophages and/or parasites) remains unclear. Two
genes that encode proteins involved in Sb reduction have been
described recently, the arsenate reductase LmACR2 and TDR1
thiol-dependent reductase [8,9]. Nevertheless, the role of these
reductases in antimony resistance is not clear. Non enzymatic Sb
reduction is also possible and probably mediated by the reducing
agents glutathione (GSH) and trypanothione (T(SH)2) [5,10,11].
Once reduced in the macrophages, Sb
III uptake is mediated by the
aquaglyceroporin1 (AQP1) [12] and downregulation of AQP1 gene
expression is correlated to resistance [13].
Increases of T(SH)2 levels have been observed in parasites
selected for resistance to Sb
III or arsenite [14]. This enhancement
is usually related to the increased levels of rate-limiting enzymes
involved in the synthesis of GSH (gamma glutamylcysteine
synthetase- c-GCS) and polyamines (ornithine decarboxylase –
ODC) [15,16]. The use of specific inhibitors of c-GCS or ODC
can revert the resistance phenotype in mutants [16]. The ATP-
binding cassette (ABC) protein MRPA has been classically related
with drug resistance in Leishmania and plays a major role in metal
resistance in these parasites [17]. MRPA is a member of the
multidrug-resistance protein (MRP) family and its localization in
intracellular vesicle membranes strongly suggests that it sequesters
Sb-thiol complexes into these vesicles [18]. The MRPA gene has
been found frequently amplified in laboratory-selected antimony-
or arsenite-resistant Leishmania mutants as well as in field isolates
[19,20,21].
Improved knowledge of the mechanisms involved in drug
resistance using laboratory-selected mutants or field isolates are
mostly derived from Old World Leishmania species such as
L. tarentolae [22], L. major [23,24], L. tropica [25], L. donovani [26],
and L. infantum [27]. On the other hand, the mechanism of drug
resistance in New World Leishmania species remains poorly
explored. Nevertheless, phenotypic and molecular characteriza-
tions of drug resistance have been recently published for human
pathogenic neotropical Leishmania species [28,29,30]. Resistance to
antimony in L. amazonensis has not been well studied as yet.
Understanding the mechanisms responsible for drug resistance in
Leishmania could support the design of new strategies for the
successful treatment of leishmaniasis as well as the identification of
molecular markers for resistance.
Considering the multiplicity of mechanisms leading to antimony
resistance, the simultaneous analysis of gene expression could
provide useful information about the antimony-resistance mech-
anisms in Leishmania and help the identification of new pathways
involved in resistance. Recent studies have demonstrated the
usefulness of whole-genome DNA microarrays for studying drug
resistance in Leishmania [31,32]. In this study, populations of
L. amazonensis resistant to Sb
III were selected in vitro in order to
study global gene expression modulation associated with antimony
resistance.
Methods
Parasite culture conditions and selection of Sb
III resistant
parasites
Leishmania amazonensis (MHOM/BR/1989/Ba199) promasti-
gotes were maintained in minimum essential culture medium (a-
MEM) (Gibco, Invitrogen, NY, USA), supplemented with 10%
(v/v) heat-inactivated fetal calf serum (Multicell, Wisent Inc.
Que ´bec, CA), 100 mg/ml kanamycin, 50 mg/ml ampicillin, 2 mM
L-glutamine, 5 mg/ml hemin, 5 mM biopterin, (Sigma-Aldrich, St
Louis, USA), pH 7.0 and incubated at 25uC in B.O.D incubators
(Johns Scientific-VWR, Toronto, CA). The parasites were kindly
provided by Dr. Aldina Barral, Gonc ¸alo Muniz Research Center,
Oswaldo Cruz Foundation, Brazil [33]. Populations of Leishmania
amazonensis promastigotes were selected for Sb
III resistance as
previously described [19]. The four independent mutants of
L. amazonensis Ba199Sb
III2700.1 to Ba199Sb
III2700.4 were indi-
vidually selected in 25 cm
2 flasks containing 5 ml of a-MEM
medium in the presence of Sb
III concentrations up to 2700 mM.
Stability and specificity of Sb
III resistance in vitro
L. amazonensis Ba199Sb mutants selected for Sb
III resistance
were grown in the absence of antimony pressure for 20 passages to
test for the resistance stability phenotype [34].
Leishmania full genome microarray design
The full genome arrays were described previously [31,32,35].
GeneDB version 3.0 of L. infantum genome and L. major genome
version 5.2 were used for the probe selection. The microarray chip
includes a total of 9173 Leishmania specific probes and control
probes and made by Agilent Technologies (Mississauga, ON, CA).
These arrays have been used successfully with several species
[31,35].
RNA extraction and cDNA labeling
Total RNA was extracted from 10
8 promastigotes during the
mid-log growth phase using RNeasy Plus mini kit (Qiagen
Sciences, Maryland, USA) as described by the manufacturer.
The quality (based on the appearance of the spectra) and quantity
of RNA were assessed using RNA 6000 Nano Assay chips on
Bioanalyzer 2100 (Agilent Technologies Santa Clara, CA, USA).
For each probe, 7 mg of RNA were converted to aminoallyl-dUTP
incorporated cDNA using random hexamers (Roche, Basel,
Switzerland) in presence of Superscript III RNase H reverse
transcriptase (Invitrogen, Carlsbad, CA, USA). Aminoallyl-dUTP
incorporated cDNA were thereafter coupled to Alexa Fluor 555 or
Alexa Fluor 647 (Invitrogen, Carlsbad, CA, USA) according to
manufacturer recommendations. Fluorescent cDNA were then
purified using the probe purification kit ArrayIt (TeleChem
Author Summary
Leishmania are unicellular microorganisms that can be
transmitted to humans by the bite of sandflies. They cause
a spectrum of diseases called leishmaniasis, which are
classified as neglected tropical diseases by the World
Health Organization. The treatment of leishmaniasis is
based on the administration of antimony-containing
drugs. These drugs have been used since 1947 and still
constitute the mainstay for leishmaniasis treatment in
several countries. One of the problems with these
compounds is the emergence of resistance. Our work
seeks to understand how these parasites become resistant
to the drug. We studied antimony-resistant Leishmania
amazonensis mutants. We analyzed gene expression at the
whole genome level in antimony-resistant parasites and
identified mechanisms used by Leishmania for resistance.
This work could help us in developing new strategies for
treatment in endemic countries where people are unre-
sponsive to antimony-based chemotherapy. The identifi-
cation of common mechanisms among different species of
resistant parasites may also contribute to the development
of diagnostic kits to identify and monitor the spread of
resistance.
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tometrically.
Microarray hybridization
The labeled and purified cDNA from L. amazonensis was mixed
with 200 mg/ml sonicated salmon sperm DNA (Agilent Technol-
ogies, Santa Clara, CA, USA); 200 mg/ml yeast tRNA (Sigma-
Aldrich Ltd, ON, CA); 1 x blocking agent buffer (Agilent
Technologies, Santa Clara, CA, USA) and 1 x hybridization
buffer (Agilent Technologies, Santa Clara, CA, USA), then mixed,
denaturated 3 min at 95uC and incubated 30 min at 37uC. Mixed
labeled cDNAs were applied in the hybridization chamber (Agilent
Technologies, Santa Clara, CA USA) and the hybridization was
performed for 24 h at 65uC into a hybridization oven (Gene-
ChipH, Stovall Life Sciences, Greensboro, NC, USA). Slides were
washed 5 min at room temperature in 0,5X SSC, 5% Triton-
X102 with gentle agitation and subsequently washed 5 min in pre-
warmed 0,1X SSC, 0,005% Triton-X102 at room temperature
with occasional stirring.
Microarray data acquisition and analysis
Detection of Alexa Fluor 555 and Alexa Fluor 647 signals were
performed on a G2565CA microarray scanner (Agilent Technol-
ogies, Santa Clara, CA, USA) at 5 mm resolution as previously
described [32]. The signal intensity data were extracted from the
primary scanned images using GenePix Pro 6.0 software (Axon
Instruments, Union City, CA, USA). Five different cDNA
preparations of each Ba199Sb mutant and their respective
Ba199 wild-type were analyzed including dye-swaps. Normaliza-
tion and statistical analyses were performed in R 2.2.1 software
using the LIMMA (Linear Models for Microarray Data) 2.7.3
package [36,37,38]. Background correction was performed using
the ‘‘edwards’’ method; within-array normalization was done by
loess and between array normalization by the Aquantile method.
Multiple testing corrections were done using the false discovery
rate method with a threshold p value of 0.05. Only genes
statistically significant with an absolute ratio greater than 1.5 were
considered. Custom R programs were used for the generation of
the chromosome expression maps. Data are available with the
GEO accession number GSE26159.
Quantitative real-time RT-PCR
Three independent RNA preparations were used for each real-
time RTPCR experiment. First-strand cDNA was synthesized
from 2.5 mg of RNA using Oligo dT12–18 and SuperScript II
RNase H-Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer protocol. Equal amounts of cDNA
were run in triplicate and amplified in 20 ml reactions containing
1 x SYBRH Green Supermix (Bio-Rad, Hercules, CA, USA),
100 nM forward and reverse primers and 1 ml cDNA target.
Reactions were carried out using a rotator thermocycler Rotor
Gene (RG 3000, Corbett Research, San Francisco, USA). Initially,
mixtures were incubated at 95uC for 5 min and then cycled 30
times at 95, 60 and 72uC for 15 sec. No-template controls were
used as recommended. Three technical and biological replicates
were established for each reaction. The relative amount of PCR
products generated from each primer set was determined based on
the threshold cycle (Ct) value and the amplification efficiencies.
Gene expression levels were normalized to constitutively expressed
mRNA encoding glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, LmjF30.2970). Primers for targeted genes MRPA
(LmjF23.0250), NT3 (LmjF13.1210) and LmjF26.2680 were de-
signed using Primer Quest
SM (www.idtdna.com/Scitools/Appli
cations/Primerquest). The sequences of the primers for MRPA are
forward 59-TGAGACACGCCGCATCAAGAGTAT-39 and re-
verse 59-TCAATGCTTCCTGCAGTACGAGGT-39; for NT3
are forward 59-AAGTTCATCTGGCCTCTCATGGCT-39 and
reverse 59-GATGGTTGCAAACCACTTGTCCGT-39; for LmjF-
26.2680 are forward 59-ACCCAGTCATTCGTCATGCACTCT-
39 and reverse 59- ATCTGGTTGACAGCGTCGCAAATG-39 ;
and for the GAPDH control forward 59-GAAGTACACG-
GTGGAGGCTG-39 and reverse 59-CGCTGATCACGACC-
TTCTTC-39.
DNA manipulations
Genomic DNA was isolated from L. amazonensis Ba199 WT and
Ba199 antimony-resistant mutants using DNazol (Invitrogen,
Carlsbad, CA, USA) following the manufacturer’s instructions.
Southern-blots and pulse field gel electrophoresis (PFGE) condi-
tions were done following standard protocols [20]. Genomic
DNAs were digested with PvuI and electrophoresed in 1% agarose
gel. The fragments were transferred to Hybond
TM-N+ membrane
(Amersham Pharmacia Biotech, Sunnyvale, CA, USA) and
submitted to Southern-blot analysis. Chromosomes of L. amazo-
nensis Ba199 WT and antimony-resistant mutants were separated
by PFGE in which low melting agarose blocks, containing
embedded cells (10
8 log phase cells/ml) were electrophoresed in
a contour clamped homogenous electric field apparatus (CHEF
Mapper, Bio-Rad, Hercules, CA, USA) in 0,5 x Tris-Borate-
EDTA, with buffer circulation at a constant temperature of 14uC
and run time of 30 h. Saccharomyces cerevisiae chromosomes were
used as size markers. DNA was transferred to nylon membranes,
cross-linked to the membrane with UV light. The blots were
hybridized with [a-
32P]dCTP labeled DNA probes. The probes
used in the present study included a 450 bp MRPA fragment and a
a-tubulin probe used to control the DNA loading.
Measurement of intracellular thiols
Intracellular thiols were analyzed by derivatizing with mono-
bromobimane and separating by high-performance liquid chro-
matography as described previously [14,39] using a chromato-
graph Shimadzu SCL 10A. Thiols were identified from bimane
fluorescence with excitation and emission at 360 and 450 nm,
respectively using a coupled fluorescence detector (Shimadzu
RF-10Axl).
Statistical analyses
The IC50 values were calculated by linear regression using the
software GraphPad Prism 5.0 and Sigma Plot 10.0 for windows.
Differences in the level of intracellular thiols were analyzed by
one-way ANOVA followed by Dunnett’s multiple comparison test
post-test using GraphPad Prism 5.0. The level of significance
acceptable was 95% (p,0.05).
Results
Characterization of resistance phenotype in laboratory-
selected antimony resistant mutants
Four independent mutants of L. amazonensis were selected step
by step for antimony (Sb
III) resistance. The IC50 value of the
sensitive Ba199 strain was 83 mM, whereas the antimony resistant-
mutants Ba199Sb
III2700.1, 2700.2, 2700.3 and 2700.4 had IC50
values greater than 2700 mM (Table 1), the highest achievable
soluble Sb
III concentration in a-MEM medium at pH 7. The
stability of the resistance phenotype was tested by growing the cells
in the absence of Sb
III. After 20 passages without drug pressure,
only the resistance in mutant Ba199Sb
III2700.2 was found to be
stable, while the other three mutants showed decreased resistance
Antimony Resistance in Leishmania amazonensis
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Ba199Sb
III2700.1, 2700.3 and 2700.4 mutants were not as
sensitive as wild-type cells to Sb
III (Table 1). The susceptibility
to miltefosine in the Sb
III-resistant L. amazonensis mutants was also
tested. None were cross-resistant but 3 out of the 4 lines were
surprisingly hypersensitive to it (Table 1). Intriguingly, we have
also observed hypersensitivity to miltefosine in L. infantum Sb
III-
resistant mutants (W. Moreira and M. Ouellette, unpublished
observations).
RNA expression profiling in Leishmania amazonensis
antimony-resistant mutants
The Ba199Sb
III2700.2 and Ba199Sb
III2700.3 lines were
selected for gene expression studies using full genome DNA
microarrays. We plotted the log2-transformed gene expression
ratios of Ba199Sb
III2700.2 (red line) and Ba199Sb
III2700.3 (blue
line) compared to Ba199WT parental strain, as a function of the
microarray probes (Fig. 1). Most genes were equally expressed but
about 10% of genes showed a statistical significant variation
(summarized in Table S1 and detailed in Tables S2 and S3) with
approximately 2-fold differential expression but some reached
log2-transformed ratio values up to 4 and 24 (Fig. 1). The
differential hybridization data were also represented on a
chromosome by chromosome basis (Figs. 2 and 3). Upregulated
and downregulated genes are indicated by red and green lines,
respectively, while equally expressed genes were shown as gray
regions. Some obvious changes in gene expression were noticed. A
specific region at one telomeric end of chromosome 23 was
Table 1. Inhibitory concentration of L. amazonensis strain
Ba199 antimony-sensitive and –resistant independent
mutants.
Strain IC50 (mM)
Sb
III Miltefosine Sb
III (rev)
Leishmania amazonensis
Ba199 WT
83 7.23 75
Ba199Sb
III2700.1 .2700
.2700
.2700
.2700
1.37 407
Ba199Sb
III2700.2 1.57 .2700
Ba199Sb
III2700.3 9.42 915
Ba199Sb
III2700.4 3.25 488
The IC50 values were also calculated for revertant parasites (rev), which were
submitted to 20 passages in absence of Sb
III. Average of at least 3
measurements with less than 5% variation.
doi:10.1371/journal.pntd.0001167.t001
Figure 1. Differential gene expression in L. amazonensis antimony resistant mutants. Overlap of log2-transformed L. amazonensis Ba199
Sb
III2700.2/WT and Sb
III2700.3/WT expression ratio plotted as a function of the chromosomal location of probes represented on the full-genome
microarrays from chromosome 1 (left end) to chromosome 36 (right end). Vertical lines represent the log2-transformed expression ratio of individual
genes. Upregulated genes are represented by positive values whereas negative values indicate downregulated genes at the RNA level. The plot
represents the average values of five independent hybridizations for each mutant.
doi:10.1371/journal.pntd.0001167.g001
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III2700.2 (Fig. 2), while most genes of
chromosome 23 seemed upregulated in Ba199Sb
III2700.3 (Fig. 3).
Chromosome aneuploidy has been described previously in Old
World drug resistant Leishmania [31,32] and the chromosome maps
of Figs. 2 and 3 suggest that this phenomenon also takes place in
New World Leishmania species with chromosomes 1, 10, 16, 27 and
31 becoming polyploids in Ba199Sb
III2700.2 (Fig. 2) while in
addition to chromosome 23, chromosomes 5, 27 and 32 are
polyploids and chromosome 4 is haploid in Ba199Sb
III2700.3
(Fig. 3). A region of chromosome 35, 250 kb from one telomeric
end, corresponds to loci where the expression of genes was down
regulated in both Ba199Sb
III2700.2 and Ba199Sb
III2700.3
mutants (Figs. 2 and 3). The expression of genes part of a region
on chromosome 33, 1.5 Mb from one telomere end was also down
regulated in both mutants (Figs. 2 and 3).
The array results led to several candidate genes putatively
correlated to resistance. Candidate genes could either be highly
differentially regulated or part of large regions differentially
regulated, as highlighted in Figs. 2 and 3. The genes common to
both mutants most differentially down regulated included the
hypotheticalproteingene LmjF26.2680and aputativelmgt2glucose
transporter gene LmjF36.6290 (Fig. 1 and Supplementary Tables S2
and S3). On the other hand, the gene common to both mutants
most upregulated was corresponding to the nucleobase transporter
NT3 LmjF13.1210. The overexpression of NT3 was confirmed by
qRT-RTPCR which yielded similar results as found with micro-
arrays with higher expression of NT3 in Ba199Sb
III2700.2
compared to 2700.3 (Fig. 1, Fig. 4). We also tested the two other
L. amazonensis mutants available and found that NT3 was also
overexpressed in Ba199Sb
III2700.1 and 2700.4 (Fig. 4). Similarly,
we confirmed the down regulation of LmjF26.2680 by qRT-
RTPCR not only in Ba199Sb
III2700.2 and 2700.3 but also in two
other L. amazonensis resistant mutants (Fig. 4). None of the genes
described above were previously linked to antimony resistance in
Leishmania. For specific larger regions that were presumed to be up
or down regulated as determined from the chromosome maps of
Figs. 2 and 3, we found that the region of chromosome 23
upregulated in Ba199Sb
III2700.2 (Fig. 2) contained several genes
(Table S2) including the ABC protein gene MRPA LmjF23.0250,a
well established marker of antimony resistance [40,41]. The MRPA
gene was also upregulated in Ba199Sb
III2700.3 (Fig. 3) as
determined by microarrays (Table S3). As discussed above, two
regionsof chromosome 35and 33appearedtobe downregulatedin
both mutants. The region of chromosome 35 encodes for several
hypothetical proteins, but also three proteophosphoglycan (PPG)
genes PPG1, PPG3 and PPG5 (Tables S2 and S3). Similarly, the
region of chromosome 33 corresponds mostly to hypothetical
proteins (Tables S2 and S3). With the exception of MRPA,n o n eo f
the genes highlighted in this study were previously linked to
antimony resistance. We searched for genes that were previously
linked to resistance with significant changes in gene expression and
found several genes that were upregulated in the Ba199Sb
III
mutants and that were involved in redox and thiol metabolism such
as peroxidoxin (LmjF23.0040), glutaredoxin (LmjF05.0310), trypa-
nothione synthetase (LmjF23.0460; LmjF27.1870), trypanothione
reductase (LmjF05.0350), and spermidine synthase (LmjF04.0580)
Figure 2. Gene expression map of L. amazonensis Ba199 Sb
III2700.2/WT. DNA microarrays data were analyzed by custom R programs to
illustrate the expression profile of Ba199Sb
III2700.2/WT by extrapolating on a chromosome map of L. major. Red lines indicate upregulated genes in
Ba199 Sb
III2700.2, whereas green lines indicate downregulated genes. Gray features indicate genes equally expressed in both samples while white
regions have not hybridized to probes.
doi:10.1371/journal.pntd.0001167.g002
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biosynthetic genes (e.g. spermidine synthase, trypanothione synthe-
tase) prompted us to quantify the level of intracellular reduced
thiols, since resistance to Sb
III is often correlated to increased
glutathione and trypanothione levels in Old World Leishmania [42].
Theantimony-resistant L.amazonensis mutants,withtheexceptionof
Ba199Sb
III2700.1 (for glutathione), had significant higher levels of
cysteine, glutathione and trypanothione (Fig. 5).
We also tested the role of genes previously not associated with
resistance, concentrating on some of the genes most differentially
expressed. These genes correspond to the hypothetical gene
LmjF26.2680 which was down regulated by more than 20-fold in
all mutants (Fig. 4) and NT3 that was overexpressed in all mutants
as determined by real-time RT-PCR (Fig. 4). Transfection of
LmjF26.2680 in wild-type L amazonensis or in its resistant mutants
did not change their susceptibilities to Sb
III (results not shown).
Similarly, transformation and overexpression of NT3, did not lead
to higher resistance to Sb
III in wild type cells (result not shown).
Increased MRPA expression mediated by gene
amplification in antimony-resistant L. amazonensis
mutants
The MRPA gene was overexpressed in both mutants (Table S2
and S3) and this upregulation was indeed confirmed by qRT-
RTPCR in Ba199Sb
III2700.2and 2700.3but MRPA was also found
overexpressed in Ba199Sb
III2700.1 and 2700.4 (Fig. 4). The fold
increased expression by qRT-RTPCR was higher than what
microarray would have suggested. Often, but not always, gene
overexpression is correlated to gene amplification in Leishmania
[13,40,41]. Southern blot analysis and careful densitometric
quantification has indeed indicated that MRPA gene copy number
is increased in the mutants compared to wild-type cells (Fig. 6A).
Increased gene copy number is usually due to the formation of
extrachromosomal circular or linear elements [43,44] although
changes in copy number of whole chromosomes have also been
reported [31,32]. Search for extrachromosomal circles failed by
standard alkaline lysis extractions and we thus relied on CHEF gels
to separate the Leishmania chromosomes and investigated for the
presence of short linear amplicons. Hybridization to a MRPA probe
showed the presence of linear amplicons in Ba199Sb
III2700.1 and
2700.2 while the whole chromosome 23 was increased in copy
number in Ba199Sb
III2700.3 and 2700.4(Fig. 6B). These results are
consistent with the microarray data (Figs. 2 and 3).
Discussion
Resistance to antimony in Leishmania has been studied mostly in
Old World species and mostly in strains in which resistance was
induced under laboratory conditions (reviewed in [5,42]).
However, with a better understanding of in vitro resistance
mechanisms, more work has recently been done with clinical
isolates and some of the markers highlighted in in vitro studies were
shown to correlate with drug resistance in clinical isolates [20,45].
In general, there is a reasonable agreement between in vitro
susceptibility testing and clinical response with Old World
Leishmania when assays are carried out with intracellular parasites
[45,46,47]. However, there are conflicting results in linking in vitro
Figure 3. Gene expression map of L. amazonensis Ba199 Sb
III2700.3/WT. DNA microarrays data were analyzed by custom R programs to
illustrate the expression profile of Ba199Sb
III2700.3/WT by extrapolating on a chromosome map of L. major. Red lines indicate upregulated genes in
Ba199 Sb
III2700.3, whereas green lines indicate downregulated genes. Gray features indicate genes equally expressed in both samples while white
regions have not hybridized to probes.
doi:10.1371/journal.pntd.0001167.g003
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leishmaniasis [48,49]. There have been few studies on mechanisms
of resistance to antimony in New World parasites and we have
thus used here the proven approach of in vitro selected resistant
cells. Four independent L. amazonensis clones were selected for
resistance to Sb
III. Resistance was in general unstable when cells
were grown in absence of the drug (Table 1), a result also recently
observed with New World Leishmania selected for antimony
resistance [28].
To find possible markers of resistance in these L. amazonensis
strains, we carried out RNA expression profiling on full genomic
DNA microarrays, a technique proven useful to study resistance
mechanisms in Leishmania [31,32,50]. We found several gene
candidates (Table S2 and S3), some for which the expression was
highly modulated in comparison to sensitive isolates. Two of these
genes (the hypothetical LmjF26.2680 and NT3) were new and were
experimentally tested by gene transfection. However, we could not
directly link them to resistance. NT3 and LmjF26.2680 were
respectively overexpressed and down-regulated in four indepen-
dent mutants (Fig. 4), and this recurrence would argue for some
role in resistance. If it is not directly involved in resistance as the
transfection work would suggest, it could either require another
product to confer resistance or it may have another more indirect
role such as in increased fitness or compensating for other
mutations. We noticed that one glucose transporter in Ba199S-
b
III2700.3 was down regulated (Fig. 1). Decrease glucose uptake,
for example by minimizing reactive oxygen species, was suggested
as a general mechanism associated with drug resistance in
L. amazonensis [51]. Future work will be required to test this. It is
also worthnoting that while the expression of NT3 is increased, this
is not due to gene amplification. Indeed, the NT3 copy number
remains similar to wild-type (result not shown). While changes in
expression in resistant isolates are often due to changes in gene
copy number, there has been several other reports of increased
expression by other means which will likely involve post-
transcriptional regulation mechanisms. Indeed, the expression of
genes in Leishmania is not controlled at the level of transcription
initiation [52,53].
The microarray work allowed detecting alterations of expres-
sion of large regions of genomic DNA and even of whole
Figure 4. RNA expression in L. amazonensis antimony resistant mutants by quantitative real time RT-PCR. The RNA expression ratios of
the nucleobase transporter gene NT3, the ABC protein MRPA gene and the hypothetical protein encoding gene LmjF26.2680 were measured in
L. amazonensis antimony resistant mutants, which were compared to levels found in WT cells. The expression of GAPDH was used to normalize the
data. The values are the mean of two independent experiments each performed with three biological RNA preparations.
doi:10.1371/journal.pntd.0001167.g004
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usually linked to changes in copy number [31,32]. One region
that attracted our attention was part of chromosome 23. Mutant
Ba199Sb
III2700.2 had a specific region that was overexpressed
while the whole chromosome 23 seemed overexpressed in
Ba199Sb
III2700.3. The gene MRPA, one marker highly corre-
lated to Sb
III resistance in Old World Leishmania,i se n c o d e db y
chromosome 23. We tested whether this increased expression
Figure 5. Intracellular levels of thiols in L. amazonensis antimony resistant mutants. Thiols were derivatized with monobromobimane and
separated by HPLC coupled with a fluorescent detector. Values are representative of two experiments performed in triplicate. Asterisks indicate
statistically significant changes compared with Ba199 WT. The data were analyzed by one-way ANOVA followed by Dunnett’s multiple comparison
test. *** = p,0.01.
doi:10.1371/journal.pntd.0001167.g005
Figure 6. Amplification of MRPA gene in antimony-resistant L. amazonensis. (A) Total genomic DNAs of Leishmania cells were digested with
PvuI, electrophoresed on agarose gel, transferred onto a membrane and hybridized with an MRPA specific probe. Southern blot hybridization was
quantified using ImageJ 1.43 (NIH) and the fold differences in DNA copy number of Ba199Sb mutants compared to WT are listed. (B) Pulsed field gel
electrophoresis (PFGE) was used to separate the chromosomes of L. amazonensis. The CHEF blot was hybridized with the same MRPA probe. The
Southern-blot membranes were washed and rehybridized with an a-tubulin probe to monitor the amount of DNA layered on the gel. Marker (M);
L. amazonensis Ba199WT (lane 1); Ba199Sb
III2700.1 (lane 2); Ba199Sb
III2700.2 (lane 3); Ba199Sb
III2700.3 (lane 4); Ba199Sb
III2700.4 (lane 5).
doi:10.1371/journal.pntd.0001167.g006
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indeed confirmed that MRPA is amplified (Fig.6A). New World
Leishmania is divided in two subgenus: Leishmania and Viannia.
Gene amplification is rare in the Viannia subgenus [30] and this
may be due to an active RNA interference (RNAi) mechanism in
this subgenus but absent in the Leishmania subgenus [54]. It is
thus surprising that there is one report of a circular extrachro-
mosomal amplification of MRPA in L. V. guyanensis selected for
antimony resistance [55]. There is, however, ample report of
gene amplification in the New World Leishmania subgenus
whether it is L. amazonensis [56,57] or L. mexicana [58]. No
MRPA amplification has been observed in one L. amazonensis
strain selected for Sb
III resistance [59] but a circular amplifica-
tion was observed in L. mexicana selected for resistance to the
related metal arsenite [58]. The MRPA containing amplicon in
L. mexicana or L. V. guyanensis corresponded to an extrachromo-
somal circle. In Ba199Sb
III2700.2 the amplification was a linear
amplicon and extended from the telomeric region to gene
LmjF23.0540 (a region of ,230 kb). All linear amplifications so
far described, indeed extended to the telomeric region and are
usually forming large inverted duplications [31]. This duplication
of the region amplified fits with the size of this linear amplicon
(Fig. 6B). Interestingly, we also found an MRPA containing linear
amplicon in Ba199Sb
III2700.1 (Fig. 6B). The amplicon is smaller,
suggesting that a different rearrangement point, usually at the
level of inverted repeats [31,60] has been used. The microarray
data indicate that the whole chromosome 23 was increased in
Ba199Sb
III2700.3 and this was corroborated by Southern blot
analysis (Fig. 6). Indeed, the CHEF showed clearly that
chromosome 23 had a higher hybridization intensity compared
to Ba199Sb
II2700.2 (Fig. 6B). Interestingly, polyploidy of
chromosome 23 was also observed in Ba199Sb
II2700.4. Intrigu-
ingly, this relatively modest increase in copy number was
nonetheless correlated to a high MRPA expression at the RNA
level (Fig. 4). Thus an increase in MRPA expression in
L. amazonensis is correlated to either the formation of extrachro-
mosomal linear amplicons or the increased ploidy of the
chromosome.
This study has shown that mechanisms of resistance to
antimony found in Old World Leishmania can also be detected in
New World species. This includes higher thiol levels (Fig. 5) and
increased expression of the ABC MRPA, whose gene product
sequesters thiol-metal conjugates into an intracellular organelle
[18]. Overexpression of several genes was found to correlate with
increased thiols [15,16,50] and overexpression of spermidine
synthase (leading to polyamines, one constituent of trypanothione)
and trypanothione synthase (supplementary Tables S2 and S3)
could contribute to the observed increased thiols. Also we noticed
that trypanothione reductase was overexpressed and this would
maintain thiols into a reduced form and this gene was found
overexpressed in field isolates [61]. Many other genes were found
to be differentially regulated although analysis of two candidates
did not allow finding a role in resistance. Nonetheless with all
microarray experiments done with several different species it
should now be possible to perform meta-analysis which could
direct at further candidates for a better understanding of antimony
resistance mechanisms in the protozoan parasite Leishmania.
The study presented here should serve as a useful basis for
analyzing antimony resistance in clinical isolates of new world
leishmaniasis. Indeed, in vitro work mostly with the promastigote
stage of old world leishmaniasis has led to a number of drug
resistant markers [5,42]. These markers were shown to confer
resistance in the amastigote or intracellular stage of the parasite
[40] and even more importantly in L. donovani field isolates
[20,61,62,63]. Since several markers were highlighted here with in
vitro resistance in L. amazonensis, it would now be possible to test
whether similar resistance mechanisms take place with drug
resistant clinical isolates of New World leishmaniasis.
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